Cargando…
Therapeutic cancer vaccination against telomerase: clinical developments in melanoma
Checkpoint inhibitors (CPIs) have revolutionized treatment outcomes for patients with malignant melanoma. Long-term follow-up shows that a substantial subset of patients who exhibit clinical responses achieve extended overall survival. Nevertheless, most patients do not achieve durable benefit from...
Autores principales: | Ellingsen, Espen Basmo, Bjørheim, Jens, Gaudernack, Gustav |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9894137/ https://www.ncbi.nlm.nih.gov/pubmed/36700456 http://dx.doi.org/10.1097/CCO.0000000000000922 |
Ejemplares similares
-
Getting personal in metastatic melanoma: neoantigen-based vaccines as a new therapeutic strategy
por: D’Alise, Anna Morena, et al.
Publicado: (2023) -
Novel strategies to improve efficacy of treatment with tumor-infiltrating lymphocytes (TILs) for patients with solid cancers
por: Tas, Liselotte, et al.
Publicado: (2023) -
Intralesional therapy for advanced melanoma: promise and limitation
por: Agarwala, Sanjiv S.
Publicado: (2015) -
Development of encorafenib for BRAF-mutated advanced melanoma
por: Koelblinger, Peter, et al.
Publicado: (2018) -
Telomerase as a Target for Therapeutic Cancer Vaccines and Considerations for Optimizing Their Clinical Potential
por: Ellingsen, Espen Basmo, et al.
Publicado: (2021)